title: From molecular understanding to clinical advances.
abstract: Big data and computational biology brought to the forefront a number of potential actionable mutations and drug targets in clear cell renal cell carcinoma in 2013. As we continue to unravel the molecular underpinnings of tumorigenesis and progression, the clinical benefits will eventually be reaped.
authors.affiliation: Genito-urinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
authors.forename: Chung-Han
authors.initials: CH
authors.lastname: Lee
authors.affiliation: Genito-urinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Motzer
mesh_terms: D000818:Animals; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000556:secondary*; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000378:metabolism*; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000473:pathology*; D019718:Receptors, CXCR4 / Q000378:metabolism*; D014157:Transcription Factors / Q000378:metabolism*; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000378:metabolism*
chemical_list: D051793:Hypoxia-Inducible Factor 1; D019718:Receptors, CXCR4; D014157:Transcription Factors; D051794:Von Hippel-Lindau Tumor Suppressor Protein